Johnson & Johnson (JNJ) return on equity (ROE)

Return on equity · fiscal 2025
32.9%

Johnson & Johnson (JNJ) earned a return on equity of 32.9% in fiscal 2025 (the year ended December 31, 2025). That is 13.2 percentage points higher than the 19.7% of fiscal 2024. Figures as of 17 Nov 2026, 23:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
32.9%
Change on fiscal 2024
+13.2 pts
Highest on record
51.1%fiscal 2023
Lowest on record
2.2%fiscal 2017
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Johnson & Johnson return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 51.1% in fiscal 2023 and the lowest 2.2% in fiscal 2017. The fiscal 2025 figure is higher than in 94% of the 18 earlier fiscal years on record, whose median is 23.4%.

History · 19 fiscal years

Return on equity by fiscal year

Johnson & Johnson return on equity (ROE), year by year

Johnson & Johnson (JNJ) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202532.9% 13.2 pts up
202419.7% 31.4 pts down
202351.1% 27.8 pts up
202223.4%—
202228.2% 5.0 pts up
202123.3%—
201925.4% 0.2 pts down
201825.6% 23.4 pts up
20172.2%—
201723.5% 1.8 pts up
201621.7%—
201423.4% 4.7 pts up
201318.7% 1.9 pts up
201216.7%—
201216.9% 6.6 pts down
201123.6% 0.7 pts down
201024.2%—
200830.5% 6.0 pts up
200724.4%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Johnson & Johnson and comparable companies
CompanyReturn on equityFiscal year
Eli Lilly LLY77.8%2025
Johnson & Johnson JNJ32.9%2025
AbbVie ABBV128.7%2024
Merck & Co MRK34.7%2025
UnitedHealth Group UNH12.8%2025
Novartis NVS30.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on JNJ

Johnson & Johnson, figure by figure

Johnson & Johnson (JNJ) overview: price, valuation and scorecardAll health care companies by market value

Johnson & Johnson return on equity (ROE): questions and answers

What is Johnson & Johnson's return on equity?

Johnson & Johnson (JNJ) earned a return on equity of 32.9% in fiscal 2025 (the year ended December 31, 2025). That is 13.2 percentage points higher than the 19.7% of fiscal 2024.

Is Johnson & Johnson's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 94% of the 18 earlier fiscal years on record, whose median is 23.4%.

What are the highest and lowest return on equity figures on record for Johnson & Johnson?

Across the 19 fiscal years on record (2007–2025), the highest was 51.1% in fiscal 2023 and the lowest 2.2% in fiscal 2017.

How is Johnson & Johnson's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Johnson & Johnson (JNJ) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/JNJ/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.